A 2022 pooled analysis of the STEP trials found that women on semaglutide 2.4 mg lost an average of 16.8% body weight at 68 weeks, while men lost 13.1%. The gap narrowed slightly when researchers controlled for baseline insulin resistance, but sex remained a significant predictor. That pattern shows up in smaller cohorts too, though the reasons are still debated.

This is general educational content. Personal health decisions should involve a qualified clinician familiar with your medical history.

Sex Differences in GLP-1 Response

Women tend to report greater appetite suppression on semaglutide, which may explain part of the weight-loss advantage. A 2023 pharmacokinetic study showed that female participants had 20–25% higher plasma concentrations of semaglutide at the same dose, likely due to differences in body composition and volume of distribution. Higher drug exposure correlates with stronger satiety signals.

Men, on the other hand, often preserve more lean mass during weight loss. DEXA scans from the STEP 1 trial showed that male participants lost 39% of their total weight as fat-free mass, compared to 28% in women. That difference matters for metabolic rate and long-term weight maintenance, even if the scale moves less dramatically.

Estrogen may also modulate GLP-1 receptor density in the hypothalamus. Rodent models suggest that estradiol upregulates GLP-1R expression, which could amplify the anorectic effect of exogenous agonists. Human data remain sparse, but the hypothesis aligns with observed sex differences in satiety hormone signaling.

Baseline Comorbidities and Trajectory Slope

Participants with type 2 diabetes consistently lose less weight on semaglutide than those without. The SUSTAIN trials, which enrolled diabetic cohorts, reported mean weight loss around 6–8% at 1.0 mg weekly. The STEP trials, which excluded diabetes, saw 12–17% at 2.4 mg. Dose accounts for some of that gap, but not all of it.

Insulin resistance appears to blunt GLP-1 efficacy. A 2023 subgroup analysis found that individuals with HOMA-IR scores above 4.5 lost 3.2 percentage points less body weight than those below 2.0, even after adjusting for baseline BMI and dose. The mechanism may involve reduced incretin receptor sensitivity or compensatory hyperinsulinemia that defends fat mass.

Hypertension and dyslipidemia, by contrast, do not seem to predict worse outcomes. A retrospective chart review of 412 patients on semaglutide found no significant difference in weight loss between those with and without baseline cardiovascular comorbidities. Blood pressure and LDL both improved in proportion to weight lost, regardless of starting values.

Dose Escalation and Plateau Timing

Most weight loss on semaglutide occurs in the first 40 weeks. After that, the curve flattens. A 2022 extension study followed STEP 1 participants out to 104 weeks and found that mean weight loss peaked at 68 weeks, then drifted upward by 1.2% over the next nine months despite continued dosing.

Faster dose escalation does not appear to improve final outcomes. A small trial compared 4-week versus 8-week titration schedules and found identical weight loss at 52 weeks, though the faster group reported more nausea in weeks 5–12. The standard 16-week ramp remains the most common protocol in clinical practice.

Some clinicians are experimenting with higher maintenance doses. Anecdotal reports from metabolic medicine forums describe patients moving from 2.4 mg to 3.0 mg or even 3.6 mg weekly after plateau, though no published data support efficacy or safety at those levels. Oral semaglutide formulations are also being tested at higher milligram doses to match subcutaneous bioavailability.

Retatrutide and Multi-Receptor Agonism

Retatrutide, a GLP-1/GIP/glucagon triple agonist, produced 24.2% mean weight loss at 48 weeks in a phase 2 trial published in mid-2023. That exceeds semaglutide's best-case outcomes by roughly 7 percentage points. Sex-stratified data from the trial showed women losing 26.1% and men 21.8%, a similar relative gap to semaglutide.

The glucagon component may explain part of the advantage. Glucagon increases energy expenditure and promotes lipolysis, which could offset the lean-mass loss seen with pure GLP-1 agonists. Early DEXA data suggest retatrutide preserves more muscle than semaglutide, though the difference is modest and the dataset is small.

Tirzepatide, a GLP-1/GIP dual agonist, sits between semaglutide and retatrutide in efficacy. The SURMOUNT-1 trial reported 20.9% mean weight loss at 15 mg weekly. Subgroup analysis showed that participants with baseline HbA1c above 6.0% lost 3.4 percentage points less than those below 5.7%, echoing the insulin-resistance penalty seen with semaglutide.

Adjunct Peptides in Weight-Loss Stacks

Some users in the biohacking community layer additional peptides onto GLP-1 protocols. MOTS-c, a mitochondrial-derived peptide, is cited in forums for improving insulin sensitivity, though human trials are limited to a single 2021 study in older adults that showed modest fasting glucose reductions.

CJC-1295 and hexarelin, both growth-hormone secretagogues, appear occasionally in weight-loss stacks. The rationale is lean-mass preservation, but a 2020 review found no consistent evidence that GH elevation prevents muscle loss during caloric restriction. Hexarelin also carries cardiac-fibrosis risk in animal models, which has not been ruled out in humans.

Stacking GLP-1 agonists with other peptides introduces pharmacokinetic unknowns. No formal interaction studies exist for semaglutide plus CJC-1295 or MOTS-c. Anecdotal reports describe variable tolerance, with some users noting increased nausea or fatigue when combining compounds.

Predictive Models and Individual Variance

A 2023 machine-learning study attempted to predict semaglutide response using baseline demographics, labs, and genetic markers. The model achieved an R² of 0.42 for weight loss at 52 weeks, meaning it explained less than half the variance. Sex, HOMA-IR, and baseline BMI were the strongest predictors, but individual trajectories still varied widely within each subgroup.

Genetic polymorphisms in the GLP-1R gene have been proposed as modulators of response. A small candidate-gene study found that carriers of the rs6923761 A allele lost 2.1 kg more than G/G homozygotes at 24 weeks, but the finding has not been replicated in larger cohorts.

Gut microbiome composition may also play a role. A 2022 pilot study profiled stool samples from 48 semaglutide users and found that higher baseline abundance of Akkermansia muciniphila correlated with greater weight loss. The association held after adjusting for diet and exercise, though causality remains unclear.

Cost remains a barrier to long-term use. Brand-name semaglutide runs around $1,200 per month in the U.S. without insurance. Compounded versions are available for $200–$400 monthly, though quality and sterility vary by supplier. Some users cycle on and off to manage expense, but weight regain after discontinuation is common.